Organizing Committee
Program
Accomodations
Location
Deadlines
Registration and Abstract Submission
Instructions
Sponsors
Travel Awards
Travel Arrangements
Home

Program

 

Wednesday, March 18, 2009

 

  • 3:00 p.m. – 6:00 p.m. Registration – Hotel Lobby, Rimrock Resort
  • 5:00 p.m. – 7:00 p.m. Welcome Reception – Salon A
    Sponsored by WellStat Biologics

 

I. Plenary Session – Salon BC

 

Chair: John Bell, OHRI

 

  • 7:00 p.m. – 7:10 p.m. Welcome and housekeeping
  • 7:10 p.m. – 8:00 p.m. Plenary Speaker

John Hiscott

Jewish General Hospital, McGill University

S1. Manipulating the Innate Immune Response to Augment Oncolytic Virus Therapies

 

II.  Clinical Progress in Oncolytic Virus Therapies – Salon BC

 

  • 8:00 p.m. – 8:50 p.m. David Kirn, Jennerex Biotherapeutics Inc.

Navigating the landscape of clinical drug discovery: no shortcuts on the road to approval

 

Thursday, March 19, 2009

 

  • 7:00 a.m – 8:30 a.m. Continental Breakfast - Salon A

 

II. Clinical Progress in Oncolytic Virus Therapies – Salon BC

 

Session chairs: Tony Reid, UCSD and David Kirn, Jennerex Biotherapeutics

 

  • 8:30 a.m. – 8:55 a.m. Evanthia Galanis, Mayo Clinic

S2. Clinical Testing of Engineered Oncolytic Measles Virus Strains

 

  • 8:55 a.m. – 9:20 a.m. Tony Reid, UCSD

S3. Response assessment in the era of targeted therapy

 

  • 9:20 a.m. – 9:45 a.m. Kevin Harrington, Institute of Cancer Research

S4. Clinical Trials with Oncolytic Virotherapy – Moving Beyond Phase I Trials into Combinations with Standard Therapeutics

 

  • 9:45 a.m. – 10:00 a.m. REFRESHMENT BREAK – Wildrose Prefunction Area

 

  • 10:00 a.m. – 10:25 a.m. Akelsei Hemminki, Cancer Gene Therapy Group.

University of Helsinki and Helsinki University Central Hospital

S5. Compassionate use oncolytic adenovirus therapy in patients with advanced and refractory solid tumors

 

  • 10:25 a.m. – 10:50 a.m. Paul Hallenbeck, Neotropix, Inc

S6. Phase I study of Seneca Valley Virus (SVV-001), a replication competent oncolytic virus, in patients with neuroendocrine (NE) cancers

 

  • 10:50 a.m. – 11:10 a.m. Invited Abstract Talk

Darren Shafren, Viralytics Ltd

S7. Phase I studies of intravenous and intratumoral administration of oncolytic Coxsackievirus A21 (CAVATAKTM) in patients with advanced cancer

 

  • 11:10 a.m. – 11:30 a.m. Invited Abstract Talk

James Burke, Billings Clinic

S8. Phase 1 Study of Multi-Dose Administration of Intravesical CG0070 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)

 

  • 11:30 a.m. – 11:50 a.m. Invited Abstract Talk

Hideki Kasuya, Nagoya University School of Medicine

S9. Phase I-II clinical trial using HF10 (Herpes Oncolytic Virus)

 

  • 11:50 a.m. – 12:10 p.m. Invited Abstract Talk

Min Liang, Shanghai Sunway Biotech Co., Ltd.

S10. The oncolytic adenovirus projects in Sunway Biotech

 

  • 12:10 p.m. - 6:00 p.m. LUNCH ON YOUR OWN/ AFTERNOON FREE

  • 6:00 p.m. – 7:00 p.m. Working Dinner Buffett – SALON BC

 

III. Mechanisms of Tumor Selective Replication – SALON BC

 

Session chairs: Mathias Gromeier, Duke University and Nori Kasahara, UCLA

 

  • 6:30 p.m.- 6:55 p.m. Ian Mohr, NYU

S11. Opportunities in oncolytic virus design exposed by translational control strategies in virus-infected cells

 

  • 6:55 p.m. – 7:20 p.m. Mathias Gromeier, Duke University

S12. Clinical trials with PVS-RIPO: targeting MAPK signaling in CNS tumors

 

  • 7:20 p.m. – 7:45 p.m. Nori Kasahara, UCLA

S13. Engineering multiple mechanisms of tumor selectivity into replication-competent retrovirus vectors

 

  • 7:45 p.m. – 8:00 p.m. NETWORKING BREAK

 

  • 8:00 p.m. – 8:25 p.m. Eckhard Wimmer, State University of New York, Stonybrook

S14. TITLE TBA

 

  • 8:25 p.m. – 8:45 p.m. Invited Abstract Talk

Ryan Cawood, University of Oxford

S15. Use of Tissue-Specific MicroRNA to Control Pathology of Wild Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells

 

  • 8:45 p.m. – 9:05 p.m. Invited Abstract Talk

Cleo Lee, University of British Columbia

S16. MicroRNA-mediated targeting of oncolytic Herpes Simplex Virus type 1 to prostate tumors

 

  • 9:05 p.m. – 9:25 p.m. Invited Abstract Talk

Elizabeth Kelly, Mayo Clinic

S17. MicroRNA-mediated Targeting for Oncolytic Virotherapy

 

  • 9:30 p.m. – 11:00 p.m. Cash Bar – Wildrose Prefunction Area

 

Friday, March 20, 2009

 

  • 7:00 a.m – 8:30 a.m. Continental Breakfast - Salon A

 

IV. Tumor Targeting and Virus/Host Interactions – Salon BC

 

Session Chairs: Grant McFadden, University of Florida and E. Antonio Chiocca, Ohio State University

 

  • 8:30 a.m. – 8:55 a.m. Grant McFadden, University of Florida

S18. Lessons from poxviruses about oncolytic virotherapy

 

  • 8:55 a.m. – 9:20 a.m. E. Antonio Chiocca, Ohio State

S19. Glioma tumor targeting by oncolytic HSV

 

  • 9:20 a.m. – 9:45 a.m. Kah-Whye Peng, Mayo Clinic

S20. Engineering the Tropism of Oncolytic Measles Virus for Enhanced Tumor Specificity

 

  • 9:45 a.m. – 10:00 a.m. REFRESHMENT BREAK

 

  • 10:00 a.m. – 10:25 a.m. David Bartlett, University of Pittsburgh

S21. Pre-clinical and early clinical results with vvDD, an oncolytic vaccinia virus

 

  • 10:25 a.m. – 10:50 a.m. Marianne Stanford, OHRI

S22. Raccoonpox virus as a novel oncolytic poxvirus

 

  • 10:50 a.m. – 11:10 a.m. Invited Abstract Talk

Sonia Wennier, University of Florida

S23. Myxoma Virus: An oncolytic virus for the treatment of pancreatic cancer

 

  • 11:10 a.m. – 11:30 a.m. Invited Abstract Talk

Maryan Moussavi, University of British Columbia

S24. Oncolytic Vesicular Stomatitis Virus causes cancer specific cell death in prostates of transgenic PTEN knock out mice

 

  • 11:30 a.m. – 11:50 a.m. Invited Abstract Talk

Arturo Maldonado, University of Cincinnati

S25. Engineering And In Vitro Validation Of an Oncolytic HSV-1 Targeted to Midkine-Positive Tumors

 

  • 11:50 a.m.- 6:00 p.m. LUNCH ON YOUR OWN/ AFTERNOON FREE

POSTER SETUP – Wildrose Prefunction Area

 

  • 6:00 p.m. – 7:00 p.m. Working Dinner Buffett – SALON BC

 

V. Barriers to Effective Oncolytic Virus Delivery – Salon BC

 

Session chairs: Len Seymour, Oxford University and Steven Russell, Mayo Clinic

 

  • 6:00 p.m. – 6:25 p.m. Len Seymour, Oxford University

S26. Efficient Systemic Delivery of Polymer-Coated Adenovirus to Disseminated Tumours

 

  • 6:25 p.m. – 6:50 p.m. Stephen Russell, Mayo Clinic

S27. Engineering negative strand RNA viruses for more effective oncolytic virotherapy

 

  • 6:50 p.m. – 7:15 p.m. David Stodjl, Children’s Hospital of Eastern Ontario

S28. Functional Genomics of the Host/Virus Interaction as Applied to Oncolytic Virus Therapy

 

7:15 p.m. – 7:30 p.m. NETWORKING BREAK

 

7:30 p.m. – 7:55 p.m. Jean Rommelaere, German Cancer Research Centre

S29. Development of oncolytic parvoviruses as cancer therapeutics

 

7:55 p.m. – 8:15 p.m. Invited Abstract Talk

Michael Muehlebach, Paul Erlich Institute

S30. Oncolytic Measles Virus: Prevention of liver tissue-destruction by MMP activation

 

8:15 p.m. – 8:35 p.m. Invited Abstract Talk

Michael Barry, Mayo Clinic

S31. Genetic and Chemical Liver Detargeting of Oncolytic Adenovirus for Systemic Therapy

 

8:30 p.m. – 10:30 p.m. POSTER SESSION – Wildrose Prefunction Area

 

Saturday, March 21, 2009

 

  • 7:00 a.m – 8:30 a.m. Continental Breakfast - Salon A

 

VI. Understanding Immunity in Oncolytic Virus Therapy – Salon BC

 

Session Chairs: Sam Rabkin, Mass General and Marianne Stanford, OHRI

 

  • 8:30 a.m. – 8:55 a.m. Richard Vile, Mayo Clinic

S32. Determining the Role of Replication in the Efficacy of Oncolytic Virotherapy

 

  • 8:55 a.m. – 9:20 a.m. Brian Lichty, McMaster University

S33. Vaccinating against an Oncolytic Virus can Enhance Therapy

 

  • 9:20 a.m. – 9:45 a.m. Sam Rabkin, Mass General

S34. Oncolytic HSV and Immunotherapy

 

  • 9:45 a.m. – 10:00 a.m. REFRESHMENT BREAK


  • 10:00 a.m. – 10:25 a.m. Alan Melcher, Leeds Institute of Molecular Medicine

S35. Immune-mediated anti-tumor activity of reovirus is independent of direct viral oncolysis and replication

 

  • 10:25 a.m. – 10:50 a.m. Steve Thorne, University of Pittsburgh

S36. Viral enhanced immune cell therapy of cancer

 

  • 10:50 a.m. – 11:10 a.m. Invited Abstract Talk

Fabrice LeBoeuf, Ottawa Health Research Institute

S37. Preinfection with oncolytic vaccinia virus primes resistant tumors for VSV oncolysis

 

  • 11:10 a.m. – 11:30 a.m. Invited Abstract Talk

Hontao Li, Mayo Clinic

S38. Oncolytic measles viruses encoding interferon ß and the thyroidal sodium iodide symporter for mesothelioma therapy

 

  • 11:30 a.m. – 11:50 a.m Invited Abstract Talk

Karen Mossman, McMaster University

S39. PML plays a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses

 

  • 11:50 a.m. – 2:00 p.m. LUNCH ON YOUR OWN

 

VII. Overcoming Barriers to Effective Oncolytic Virus Therapy – Salon BC

 

Session Chairs: John Bell, OHRI and Peter Forsyth, University of Calgary

 

  • 2:00 p.m. – 2:25 p.m. Balveen Kaur, Ohio State

S40. Impact of tumor microenvironment on OV therapy

 

  • 2:25 p.m. – 2:50 p.m. Peter Forsyth, University of Calgary

S41. Rapamycin Enhanced the Myxoma Virotherapy for Temozolomide Resistant Brain Tumor Initiating Cells (BTICs) in vivo

 

  • 2:50 p.m. – 3:15 p.m. John Bell, Ottawa Health Research Institute

S42. Affects of Oncolytic Virus Infection on Tumour Vasculature and Blood Flow

 

  • 3:15 p.m. – 3:30 p.m. NETWORKING BREAK

 

  • 3:30 p.m. – 3:55 p.m. Savio Woo, Mount Sinai NY

S43. Oncopathic Bacteriotherapy for Pancreatic Cancer

 

  • 3:55 p.m. – 4:15 p.m. Invited Abstract Talk

Roberto Cattaneo, Mayo Clinic

S44. CD20-targeted virus eliminates primary mantle cell lymphoma xenografts by amplifying locally the therapeutic effects of fludarabine and cyclophosphamide

 

  • 4:15 p.m. – 4:35 p.m. Invited Abstract Talk

Markus Vähä-Koskela, OHRI

S45. Attenuated Semliki Forest virus for glioblastoma targeting

 

  • 4:35 p.m. - 4:55 p.m. Invited Abstract Talk

Jayson Hardcastle, Ohio State

S46. Vasculostatin expression mediated by Oncolytic HSV inhibits tumor growth and angiogenesis.

 

  • 4:55 p.m. – 7:00 p.m. NETWORKING BREAK

 

  • 7:00 p.m. – 8:30 p.m. BANQUET- Salon A

Sponsored in part by IDT Biologika GmbH

  • 8:30 p.m.- 9:00 p.m. Special ‘Surprise’ Guest Speaker

Sunday, March 22, 2009

 

  • 11:00 a.m. Posters must be removed from posterboards – Wildrose Prefunction Area

 

  • 12:00 p.m. Check out time for the hotel